Intelligence Ventures

We strive to invest in companies that develop innovative drugs, medical devices and diagnostics. We focus on generating strong financial returns from our portfolio of venture companies. We invest in both private and public companies from an open evergreen fund. This funding structure enables us to take a long-term perspective. With colleagues on the ground in Copenhagen, London, Singapore, San Francisco and Boston, we are well positioned in the major global life science hubs and can quickly respond to new and exciting investment opportunities wherever they emerge. We primarily invest in biotechnology and medical technology. Within biotech we primarily invest in companies with clinical stage compounds. In medtech, we invest in commercial stage companies. We work actively with the companies we invest in by serving on the Boards of Directors. Companies can also draw on our extensive network, as well as our commercial and scientific expertise within the life sciences. During 2021, Novo Ventures executed 46 investments. We deployed DKK 3.2 billion during the year. Investment highlights include: Verve Therapeutics, a gene editing company hoping to lower LDL cholesterol for familial hypercholesterolemia and one of the first in vivo gene editing therapies to begin clinical trials Hummingbird Biosciences, a company using a systems biology approach to antibody discovery and development, and our first venture portfolio company with headquarters in Asia Numab Therapeutics, a next generation antibody fragment platform company whose lead programme has the potential to become new standard of care in immune checkpoint therapy Noom, a leading, high growth, global digital health platform

LiquidMetal Ventures is a newly established venture capital fund based in Boston, aiming at investing in early-stage (Seed, Angel, and pre-A round) in a minority group, particularly deep-tech startups. LiquidMetal Ventures is based on deep-tech start-up communities and has a unique advantage in reaching out to ‘off-the-market’ early-stage deals and cooperating with peer VC funds tightly to reduce the risk, overall a high return could be expected. LiquidMetal Ventures focuses on biotech and healthcare, carbon neutrality, AI and data, infrastructure, and consumer tech. There is a huge tide of startups among Boston entrepreneurs in the US on the way. We would like to be the first to check VC with the founders. Investment FocusBioTech Medical Device Sustainability AI & Data Science Advanced Energy Technology Robotics & Advanced Manufacturing

We are in the midst of technological shifts at a pace faster than ever before. Calculus VC capitalizes on these shifts to deliver returns and impact. We invest in the Series A and Series B stages of startups in the below sectors: FUTURE OF COMPUTING AND AI Continued advancements in AI will demand new developments in hardware and software. New computing materials and interfaces may emerge. Computing power may be more distributed, and the world will be infinitely more connected. These and more, are our areas of interest: Intelligence beyond language: We expect AI to understand quantitative models and physical phenomenon just as well as it understands language. Large Quantitiative Models are a focus for us. New hardware, materials, and architectures: We expect that demand for computing power will grow exponentially. Quantum computing, as well as distributed computing are expected to grow. We expect advancements in computing materials beyond silicon. Immersive and neural interfaces: These interfaces already exist, we expect they will become more mainstream. Spatial computing, integrating the physical world with digital environments may be our future. COMPUTATIONAL LIFE SCIENCES AND HEALTHTECH Breakthroughs in biology, materials, sensors, and data science are converging to redefine healthcare. Precision and personalization will take center stage as AI enhances how we detect, monitor, and treat disease. Areas of interest include: AI-First Therapeutics and Discovery Platforms: ML-powered platforms designing drugs and biologics via simulation, predictive modeling, and data-rich experimentation. Infrastructure for Programmable Biology: Tools that make biology engineerable – lab automation, bioinformatics, 3D bioprinting, next-gen diagnostics and R&D devices. Continuous, Data-Driven and Personalized Care: Wearables, medical devices, and diagnostics to deliver patient-centric care. These models turn users into real-time data streams, enabling adaptive treatment and personalized interventions. ADVANCED INDUSTRIAL TECHNOLOGIES As we expand the frontiers of possibility, we expect industry to evolve with intelligence, autonomy and environmental sustainability at its core. Areas of focus include: AI and automation in industry: Intelligent machines will optimize production, reduce waste, and enable new workflows. From predictive maintenance to robotic manufacturing, automation will power the next industrial revolution. We support startups enabling this vision. Land, ocean, and space transport and communications: We are interested in advanced materials, robotics, sensors, systems and software that will unlock new frontiers from deep-sea mapping to planetary missions. Resource efficiency: Building the future will demand large reserves of energy and natural resources. Technologies that can serve our energy, food, water, and agricultural needs while supporting a better planet are of interest to us.

Backed by a grant from the U.S. Economic Development Administration, RightHill Ventures works in partnership with Brown, the University of Rhode Island, and other higher education institutions and their alumni to identify and fund the innovators who are developing solutions to some of the world's most challenging problems. Established by the Slater Technology Fund, a regional seed investor with deep roots in the Brown ecosystem, RightHill Ventures recruits key players from the national pool of industry and entrepreneurial talent – individuals from the broadest community – to prove our potential, build teams, and help us fuel them through early milestones. We believe that the power of university research, coupled with RightHill’s tight focus and the strength of the larger community, will result in bold launches powered by individualized investment syndicates. Leveraging Our Network of Partners Our deep ties to Brown and URI's scientific, engineering, and clinical faculty, as well as to all elements of their-and the region's-entrepreneurial ecosystem, allow us to identify the most promising innovations and connect them with the right resources to help them grow into successful companies.

Intuitive Ventures invests in and accelerates the digital, therapeutic, diagnostic, and device ecosystems of minimally invasive care. Our unique access to Intuitive’s industry-leading knowledge, care delivery innovation, and commercial reach, empowers us to cultivate the potential of startups that are advancing positive outcomes in healthcare. Through our inaugural $100 million fund, Intuitive Ventures is focused on accelerating the future of minimally invasive care by moving the ecosystem forward. What we do Intuitive Ventures extends Intuitive's commitment to converging robotic systems, digital tools, and clinical need in search of new ways to understand, diagnose, treat, and manage disease. We apply Intuitive’s strengths and abilities in the fields of robotic surgery and minimally invasive care to support independent initiatives in four focus areas: Digital – transformative business models and solutions improving outcomes across the patient care continuum Therapeutics – precision focal therapeutics and biotech innovations delivered to the right patient at the right place and the right time Diagnostics – powering earlier disease detection and therapeutic activation across clinical pathways Devices – novel and digitally-native medical device platforms pushing the boundaries of patient care What sets us apart: Aligned for success – our nimble structure and financial alignment empower us to invest early and to support our portfolio companies pioneer markets Wealth of experience – we provide the resources and guidance needed to support our entrepreneurs and management teams reach their major milestones Deep strategic value – we leverage the unique strengths of Intuitive to accelerate the impact of our portfolio companies

Established in 2023, KP Rx is a 100% founder-owned investment firm specialising in private and early-stage public healthcare investments in Australia and New Zealand. Founded by Hashan De Silva and backed by Karst Peak Capital, the firm targets high-potential biotech, medical devices, diagnostics, and health tech companies at a pivotal inflection point of value creation. Our Focus Creating a portfolio of Australia’s most promising healthcare companies. Our focus is on companies at or after Series A, specifically biotech companies at Phase 2 or medical device companies at or after regulatory clearance. Small-molecule Drugs Biological Products Cell & Gene Therapies Medical Devices Diagnostic Technologies AI for Healthcare Healthcare Software / SaaS Data and Analytics